{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"3.6","value":"2.8"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"6.9","value":"5.4"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"5.4","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG001","title":"Docetaxel + Ramucirumab DP"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG002","title":"Docetaxel + Icrucumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who received at least one dose of study drug. Participants censored: docetaxel arm = 40; docetaxel and ramucirumab arm = 34; docetaxel and Icrucumab arm = 41.","reportingStatus":"POSTED","timeFrame":"Randomization to Measured PD or Death From Any Cause (Up To 40 Months)","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}